GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Eptifibatide

Local RX List renal extractBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

Integrilin

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
A renal infusion reduction is not a dialysis allowance

The infusion adjustment concerns low clearance in eligible adults. Dialysis dependency appears separately in the contraindications.

Before applying: Check dialysis status and bleeding contraindications before applying the infusion reduction. Retain bolus, duration and co-antithrombotic rules from the same protocol.

Also check: A renal infusion reduction is not a dialysis allowance

Rxlist source

GlobalRPh RX List - INTEGRILIN

Product / population
Adult intravenous eptifibatide for ACS/PCI; infusion adjustment, not a complete antithrombotic order set.
Renal measure
Cockcroft-Gault CrCl in mL/min.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

At CrCl below 50 mL/min, reduce the infusion to 1 mcg/kg/min. The indication-specific 180 mcg/kg bolus instructions are not reduced by this renal rule; PCI includes its specified second bolus. Dialysis dependency is a contraindication, not an invitation to extend the low-clearance infusion band. Bleeding risk, other antithrombotics, platelet counts and full treatment-duration instructions require separate review.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/integrilin-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - INTEGRILIN

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult intravenous eptifibatide for ACS/PCI; infusion adjustment, not a complete antithrombotic order set.

Renal method: Cockcroft-Gault CrCl in mL/min.
Retrieved: 2026-09-07

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

dialysis context

A renal infusion reduction is not a dialysis allowance

The infusion adjustment concerns low clearance in eligible adults. Dialysis dependency appears separately in the contraindications.

How to use this: Check dialysis status and bleeding contraindications before applying the infusion reduction. Retain bolus, duration and co-antithrombotic rules from the same protocol.

GlobalRPh RX List - INTEGRILIN

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - INTEGRILIN
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The unusual source weight-cap threshold and bolus maximum are preserved, not recalculated.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/eptifibatide/

Usual Dosing (Adults)

The source efficacy/safety studies used concomitant heparin and aspirin, with different regimens in major studies.

PCI, normal renal function: 180 micrograms/kg IV bolus immediately before PCI, then 2 micrograms/kg/min continuous infusion plus a second 180 micrograms/kg bolus 10 minutes after the first. Continue until discharge or 18 to 24 hours, whichever first; minimum 12 hours recommended. For weight >121 kg, source maximum 22.6 mg per bolus and 15 mg/hour infusion.

Acute coronary syndrome: 180 micrograms/kg IV as soon as possible after diagnosis, then 2 micrograms/kg/min until discharge or CABG initiation, up to 72 hours. If PCI occurs during therapy, continue until discharge or 18 to 24 hours after PCI, allowing up to 96 hours total. The same source maximum bolus 22.6 mg and infusion 15 mg/hour applies at weight >121 kg.

Stop infusion before CABG surgery.

GRPH-eptifibatide-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

Use Cockcroft-Gault with actual body weight: male CrCl (mL/min) = weight (kg) x (140 - age) / [72 x serum creatinine (mg/dL)]; women multiply by 0.85.

Source summary CrCl >50 mL/min: no change. For CrCl <50:

PCI: 180 micrograms/kg IV bolus (maximum 22.6 mg) just before procedure, then 1 microgram/kg/min (maximum 7.5 mg/hour), plus a second 180 micrograms/kg bolus (maximum 22.6 mg) 10 minutes later. Discontinue before CABG.

ACS: 180 micrograms/kg IV bolus (maximum 22.6 mg) promptly after diagnosis, then 1 microgram/kg/min (maximum 7.5 mg/hour).

GRPH-eptifibatide-02 · Source section: Renal DosingRenal section finder

Hemodialysis

Contraindicated in patients on dialysis.

GRPH-eptifibatide-03 · Source section: HemodialysisRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - INTEGRILIN

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult intravenous eptifibatide for ACS/PCI; infusion adjustment, not a complete antithrombotic order set.

Renal method: Cockcroft-Gault CrCl in mL/min.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

At CrCl below 50 mL/min, reduce the infusion to 1 mcg/kg/min. The indication-specific 180 mcg/kg bolus instructions are not reduced by this renal rule; PCI includes its specified second bolus. Dialysis dependency is a contraindication, not an invitation to extend the low-clearance infusion band. Bleeding risk, other antithrombotics, platelet counts and full treatment-duration instructions require separate review.

RDM43-rxlist-eptifibatide-a2b347b1fc-C1 · Source locator: Selected Dosage / Renal Impairment / Warnings sections; see source-specific qualifications in this summary.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/integrilin-drug/
Retrieved
2026-09-07
Renal-function method
Cockcroft-Gault CrCl in mL/min.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
6088c6d67003059b44c6f6894d0bb40b5712b38af1a6f9afa315d794ef8ad75d

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/eptifibatide/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
a4bf5269b4ff78345921fa1f6c43a8e45767212aedcf610a488514e71d6d2663
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report